Skip to main content

Table 2 BP ND of [ 11 C]AF150(S) without and with pre-treatment with agents that increase extracellular levels of ACh

From: [11C]AF150(S), an agonist PET ligand for M1 muscarinic acetylcholine receptors

Brain region Haloperidol AF-DX 384 AF-DX 384 and rivastigmine
  (1 mg kg −1SC) (5 mg kg −1IP) (5 mg kg −1IP and 2.5 mg kg −1SC)
  Baseline Pre-treated Baseline Pre-treated Baseline Pre-treated
Left striatum 0.23 ± 0.04 0.18 ± 0.01 0.27 ± 0.06 0.32 ± 0.04 0.25 ± 0.05 0.27 ± 0.03
Right striatum 0.28 ± 0.05 0.21 ± 0.03* 0.30 ± 0.04 0.33 ± 0.05 0.23 ± 0.05 0.29 ± 0.03*
Hippocampus 0.19 ± 0.02 0.16 ± 0.01* 0.26 ± 0.04 0.26 ± 0.02 0.22 ± 0.02 0.25 ± 0.01*
Frontal cortical area 0.10 ± 0.06 0.06 ± 0.04 0.24 ± 0.02 0.24 ± 0.06 0.17 ± 0.03 0.21 ± 0.02**
Posterior cortical area 0.07 ± 0.07 0.06 ± 0.04 0.21 ± 0.03 0.22 ± 0.05 0.19 ± 0.04 0.19 ± 0.04
  1. Data are presented as mean ± SD (n = 4 per group). SC, subcutaneous; IP, intraperitoneal. Significant difference compared with baseline: * p < 0.05, ** p < 0.01.